Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06339086

Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

A Multicenter, Randomized, Open-label and Parallel-controlled Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in the Treatment of Type 2 Diabetes Subjects With Poor Glycemic Control on Metformin

Sponsor: Chengdu Brilliant Pharmaceutical Co., Ltd.

Conditions Type 2 Diabetes Mellitus

Interventions Metformin Semaglutide Injection Semaglutide Injection(Ozempic®)

Updated 3 times since 2024 Last updated: Mar 24, 2024 Started: Apr 30, 2024 Primary completion: Aug 30, 2025 Completion: Dec 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06339086, this PHASE3 trial focuses on Type 2 Diabetes Mellitus and remains actively recruiting participants. Sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd., it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chengdu Brilliant Pharmaceutical Co., Ltd.

Data source: Chengdu Brilliant Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.